Clinical trials: Malignant Skin Melanoma T0
Malignant Skin Melanoma T0, Basal Cell Carcinoma
DERM US and EU Validation Study
This study aims establish the effectiveness of Image Analysing Algorithm (DERM) to identify melanoma, Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) when used to analyse dermoscopic images of skin lesions within the…
- Conditions
- Malignant Skin Melanoma T0, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT05126173
- Testing
- Deep Ensemble for the Recognition of Malignancy (DERM)
- Where
- 16 sites in United States, Italy
- Volunteers
- 1,111 people
- Sponsor
- Skin Analytics Limited
Malignant Skin Melanoma T0, Stage III Melanoma
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT…
- Conditions
- Malignant Skin Melanoma T0, Stage III Melanoma, Stage IV Melanoma, Amplification
- Trial name
- NILOMEL (NCT01168050)
- Testing
- Nilotinib
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris